Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma

Present and future

J. P. Neijt, A. C M van Lindert, C. P J Vendrik, K. J. Roozendaal, A. Struyvenberg, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

In patients with advanced ovarian carcinoma, combination chemotherapy seems to be superior to monotherapy with melphalan. This paper discusses our experience with the Hexa-CAF combination, and the results obtained in 27 evaluable patients. As first-line chemotherapy the Hexa-CAF schedule gives improved response rates, but an increase in overall survival has not yet been shown. In previously treated patients the Hexa-CAF combination is not useful because of the poor response rate and the severe toxicity. Two interesting new combinations containing cis-platinum diaminodichloride (CDDP) are promising alternatives for these patients. In previously untreated patients, favourable results can be expected from the combinations under study with hexamethylmelamine, adriamycin, and CDDP. Until more data are available treatment with combination chemotherapy ought to be restricted to specialized centres. Apart from new powerful drug combinations, the outlook for the patient with advanced ovarian carcinoma can be improved by surgical resection of the main bulk of the tumour prior to chemotherapy.

Original languageEnglish (US)
Pages (from-to)38-44
Number of pages7
JournalNetherlands Journal of Medicine
Volume22
Issue number2
StatePublished - 1979
Externally publishedYes

Fingerprint

Combination Drug Therapy
Carcinoma
Pharmaceutical Preparations
Altretamine
Drug Therapy
Melphalan
Drug Combinations
Doxorubicin
Cisplatin
hexa CAF protocol
Appointments and Schedules
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neijt, J. P., van Lindert, A. C. M., Vendrik, C. P. J., Roozendaal, K. J., Struyvenberg, A., & Pinedo, H. M. (1979). Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: Present and future. Netherlands Journal of Medicine, 22(2), 38-44.

Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma : Present and future. / Neijt, J. P.; van Lindert, A. C M; Vendrik, C. P J; Roozendaal, K. J.; Struyvenberg, A.; Pinedo, H. M.

In: Netherlands Journal of Medicine, Vol. 22, No. 2, 1979, p. 38-44.

Research output: Contribution to journalArticle

Neijt, JP, van Lindert, ACM, Vendrik, CPJ, Roozendaal, KJ, Struyvenberg, A & Pinedo, HM 1979, 'Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: Present and future', Netherlands Journal of Medicine, vol. 22, no. 2, pp. 38-44.
Neijt JP, van Lindert ACM, Vendrik CPJ, Roozendaal KJ, Struyvenberg A, Pinedo HM. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: Present and future. Netherlands Journal of Medicine. 1979;22(2):38-44.
Neijt, J. P. ; van Lindert, A. C M ; Vendrik, C. P J ; Roozendaal, K. J. ; Struyvenberg, A. ; Pinedo, H. M. / Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma : Present and future. In: Netherlands Journal of Medicine. 1979 ; Vol. 22, No. 2. pp. 38-44.
@article{0578e20a227c4fb1be6dd44d65f0e5c6,
title = "Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: Present and future",
abstract = "In patients with advanced ovarian carcinoma, combination chemotherapy seems to be superior to monotherapy with melphalan. This paper discusses our experience with the Hexa-CAF combination, and the results obtained in 27 evaluable patients. As first-line chemotherapy the Hexa-CAF schedule gives improved response rates, but an increase in overall survival has not yet been shown. In previously treated patients the Hexa-CAF combination is not useful because of the poor response rate and the severe toxicity. Two interesting new combinations containing cis-platinum diaminodichloride (CDDP) are promising alternatives for these patients. In previously untreated patients, favourable results can be expected from the combinations under study with hexamethylmelamine, adriamycin, and CDDP. Until more data are available treatment with combination chemotherapy ought to be restricted to specialized centres. Apart from new powerful drug combinations, the outlook for the patient with advanced ovarian carcinoma can be improved by surgical resection of the main bulk of the tumour prior to chemotherapy.",
author = "Neijt, {J. P.} and {van Lindert}, {A. C M} and Vendrik, {C. P J} and Roozendaal, {K. J.} and A. Struyvenberg and Pinedo, {H. M.}",
year = "1979",
language = "English (US)",
volume = "22",
pages = "38--44",
journal = "Netherlands Journal of Medicine",
issn = "0300-2977",
publisher = "Van Zuiden Communications BV",
number = "2",

}

TY - JOUR

T1 - Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma

T2 - Present and future

AU - Neijt, J. P.

AU - van Lindert, A. C M

AU - Vendrik, C. P J

AU - Roozendaal, K. J.

AU - Struyvenberg, A.

AU - Pinedo, H. M.

PY - 1979

Y1 - 1979

N2 - In patients with advanced ovarian carcinoma, combination chemotherapy seems to be superior to monotherapy with melphalan. This paper discusses our experience with the Hexa-CAF combination, and the results obtained in 27 evaluable patients. As first-line chemotherapy the Hexa-CAF schedule gives improved response rates, but an increase in overall survival has not yet been shown. In previously treated patients the Hexa-CAF combination is not useful because of the poor response rate and the severe toxicity. Two interesting new combinations containing cis-platinum diaminodichloride (CDDP) are promising alternatives for these patients. In previously untreated patients, favourable results can be expected from the combinations under study with hexamethylmelamine, adriamycin, and CDDP. Until more data are available treatment with combination chemotherapy ought to be restricted to specialized centres. Apart from new powerful drug combinations, the outlook for the patient with advanced ovarian carcinoma can be improved by surgical resection of the main bulk of the tumour prior to chemotherapy.

AB - In patients with advanced ovarian carcinoma, combination chemotherapy seems to be superior to monotherapy with melphalan. This paper discusses our experience with the Hexa-CAF combination, and the results obtained in 27 evaluable patients. As first-line chemotherapy the Hexa-CAF schedule gives improved response rates, but an increase in overall survival has not yet been shown. In previously treated patients the Hexa-CAF combination is not useful because of the poor response rate and the severe toxicity. Two interesting new combinations containing cis-platinum diaminodichloride (CDDP) are promising alternatives for these patients. In previously untreated patients, favourable results can be expected from the combinations under study with hexamethylmelamine, adriamycin, and CDDP. Until more data are available treatment with combination chemotherapy ought to be restricted to specialized centres. Apart from new powerful drug combinations, the outlook for the patient with advanced ovarian carcinoma can be improved by surgical resection of the main bulk of the tumour prior to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0018741597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018741597&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 38

EP - 44

JO - Netherlands Journal of Medicine

JF - Netherlands Journal of Medicine

SN - 0300-2977

IS - 2

ER -